neurobo pharmaceuticals gemphire therapeutics

This communication shall not constitute an offer to sell, the solicitation of an offer to sell or an offer to buy or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The actual allocation will be subject to adjustment based on Gemphire’s net cash balance at the time of the closing of the merger as well as any additional Series B capital above the minimum required amount and up to a total of $50 million that NeuroBo may secure at or before the closing of the merger. NeuroBo is focused on the development of a treatment for diabetic … The company’s current pipeline consists of three therapeutic programs targeting pain indications, Alzheimer’s disease and dyslipidemias. In addition, the forward-looking statements included in this press release represent Gemphire’s and NeuroBo’s views as of the date hereof. Initiation of enrollment in the first Phase 3 study with NB-01 is anticipated in the first half of 2020 and will enroll approximately 460 subjects with PDN across the U.S. NeuroBo’s IND-ready second drug candidate, NB-02, is targeted for the treatment of Alzheimer’s disease and neurodegenerative diseases associated with the pathological dysfunction of tau proteins in the brain. NeuroBo Pharmaceuticals & Gemphire Therapeutics Merger Building a pipeline of treatment candidates for neurodegenerative diseases that affect millions of patients worldwide Novel Treatment Candidates for Neurodegenerative Conditions July 2019. We evaluated numerous potential merger partners and recognized that NeuroBo has a solid base of investors and the potential to deliver significant value based on its pipeline assets. The company’s novel lead program, NB-01, is an oral drug candidate for painful diabetic neuropathy (PDN). Additional information about Gemphire’s directors and executive officers is included in Gemphire’s Annual Report on Form 10-K for the year that ended December 31, 2018, filed with the SEC on March 18, 2019. Transaction to Create Nasdaq-listed Biotechnology Company Focused on Advancing NeuroBo’s Clinical-Stage Pipeline, NeuroBo Poised to Advance Lead Drug Candidate into Phase 3 Trials for Neuropathic Pain Indications, NeuroBo Recently Received Aggregate Gross Proceeds of $24.24 Million in Series B Financing, Gemphire Out-Licenses Gemcabene to Beijing SL Pharmaceutical Co. for Chinese Market, Companies to Host Conference Call at 8:30 a.m. NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on multimodal, disease-modifying therapies for neurodegenerative diseases, today reported that the previously announced merger between NeuroBo Pharmaceuticals, Inc., (“NeuroBo”) and Gemphire Therapeutics (Nasdaq: GEMP) closed on December 31, 2019.The new combined company, known as NeuroBo Pharmaceuticals … INVESTORS AND STOCKHOLDERS OF GEMPHIRE AND NEUROBO ARE URGED TO READ THESE MATERIALS CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT GEMPHIRE, NEUROBO, THE PROPOSED MERGER AND RELATED MATTERS. NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on multimodal, disease-modifying therapies for neurodegenerative diseases, today reported that the previously announced merger between NeuroBo Pharmaceuticals, Inc., ("NeuroBo") and Gemphire Therapeutics (Nasdaq: GEMP) closed on December 31, 2019. In addition, investors and shareholders will be able to obtain free copies of the proxy statement/prospectus/information statement and other documents filed by Gemphire with the SEC by written request to: Gemphire Therapeutics Inc., 17199 N. Laurel Park Drive, Suite 401, Livonia, MI, 48152, Attention: Corporate Secretary. NeuroBo Pharmaceuticals was jointly founded by Dr. Roy Freeman, professor of neurology at Harvard Medical School and renowned expert in neuropathic pain, and JK BioPharma Solutions, a biotechnology consulting company, to commercialize natural product-based research into ethical medicines. Gemphire is a clinical-stage biopharmaceutical company that is committed to helping patients with cardiometabolic disorders, including dyslipidemia and NASH. Phase 3 clinical trials are expected to begin in the fourth quarter of 2019. NeuroBo Pharmaceuticals has completed its previously announced combination with Gemphire Therapeutics. View source version on businesswire.com:https://www.businesswire.com/news/home/20200110005495/en/, KEYWORD: MASSACHUSETTS UNITED STATES NORTH AMERICA, INDUSTRY KEYWORD: BIOTECHNOLOGY OTHER HEALTH HEALTH PHARMACEUTICAL CLINICAL TRIALS, PUB: 01/10/2020 05:00 PM/DISC: 01/10/2020 05:00 PM, http://www.businesswire.com/news/home/20200110005495/en. Following the merger, John L. Brooks III will be appointed to serve as the post-merger combined company’s president and chief executive officer. Posted on 01/10/2020 342 . The combined unit will operate as NeuroBo Pharmaceuticals with NeuroBo shareholders holding a 96.24% stake in the firm. The AP news staff was not involved in its creation. NeuroBo Pharmaceuticals, Inc., formerly Gemphire Therapeutics Inc., is a clinical-stage biotechnology company. BOSTON-- (BUSINESS WIRE)-- NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on multimodal, disease-modifying therapies for neurodegenerative diseases, today reported that the previously announced merger between NeuroBo Pharmaceuticals, Inc., (“NeuroBo”) and Gemphire Therapeutics (Nasdaq: GEMP) closed on December 31, 2019. “As we move towards developing both NB-01 and NB-02, we believe that having shares publicly traded on Nasdaq will provide greater opportunity to advance our therapeutic pipeline and corporate strategy.”. Gemphire and NeuroBo will host a conference call at 8:30 a.m. NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on multimodal, disease-modifying therapies for neurodegenerative diseases, today reported that the previously announced merger between NeuroBo Pharmaceuticals, Inc., (NeuroBo) and Gemphire Therapeutics (Nasdaq: GEMP) closed on December 31, 2019. These documents are available free of charge at the SEC website (www.sec.gov) and from the Corporate Secretary of Gemphire at the address above. Additionally, the live, listen-only webcast of the conference call can be accessed by visiting the investors and media section of the Gemphire website at www.gemphire.com, or the investors and media section of the NeuroBo website at www.neurobopharma.com. The merged firm will advance NeuroBo’s clinical-stage drug candidates for neurodegenerative disorders. ET on July 25, 2019. After the merger, NeuroBo investors will own 95.94% of the new company, while Gemphire shareholders will own around 4.06%. Two Phase 2b trials supporting hypercholesterolemia and one Phase 2b trial in SHTG were recently completed under NCT02722408, NCT02634151 and NCT02944383, respectively. On July 24 th, we announced the signing of a merger agreement with NeuroBo Pharmaceuticals, Inc. for an all-stock transaction expected to close later this year,” noted Steven Gullans, Ph.D., CEO of Gemphire. ET on July 25, 2019 to discuss the proposed merger transaction. Investors and stockholders are urged to read the proxy statement/prospectus/information statement and the other relevant materials when they become available before making any voting or investment decision with respect to the proposed transaction. Gemphire Therapeutics has agreed to merge with biotechnology company NeuroBo Pharmaceuticals in an all-stock transaction. Ashley RobinsonLifeSci Advisors LLC(617) 535-7742, Nicole FranklinRacepoint Global(617) 624-3264nfranklin@racepointglobal.com. Investors and shareholders will be able to obtain free copies of the proxy statement/prospectus/information statement and other documents filed by Gemphire with the SEC (when they become available) through the website maintained by the SEC at www.sec.gov. NeuroBo Pharmaceuticals Inc. is focused on novel treatments for neurodegenerative diseases affecting millions of patients worldwide. These factors, risks and uncertainties include, but are not limited to: NeuroBo’s plans to develop and commercialize its product candidates; the timing of completion of NeuroBo’s planned clinical trials; the timing of the availability of data from NeuroBo’s clinical trials; NeuroBo’s plans to research, develop and commercialize its current and future product candidates; NeuroBo’s ability to successfully collaborate with existing collaborators or enter into new collaborations and to fulfill its obligations under any such collaboration agreements; the clinical utility, potential benefits and market acceptance of NeuroBo’s product candidates; NeuroBo’s commercialization, marketing and manufacturing capabilities and strategy; the impact of government laws and regulations; NeuroBo’s ability to protect its intellectual property position; and NeuroBo’s need for additional financing to fulfill its stated goals; and other factors discussed in the “Risk Factors” section of SEC filings the combined company makes with the SEC from time to time. Gemphire Therapeutics Inc. and Boston-based NeuroBo Pharmaceuticals Inc. have agreed to a deal that will result in Gemphire changing its name to NeuroBo Pharmaceuticals. The first study in our Phase 3 program for our lead drug candidate, NB-01, for painful diabetic neuropathy (PDN), will begin screening patients soon in the U.S. and we are designing a first-in-human trial for NB-02, targeted at Alzheimer’s disease and diseases associated with the pathological dysfunction of tau proteins in the brain.”. Forward-looking statements are usually identified by the use of words, such as “believes,” “anticipates,” “expects,” “intends,” “plans,” “may,” “potential,” “will,” “could” and similar expressions. As part of the merger, Gemphire stockholders received non-transferable contingent value rights (CVRs) entitling the holders to receive in aggregate, after the retention of $500,000 by the combined company and certain other permitted deductions, 80% of the net proceeds, if any, in the event the gemcabene assets are sold or licensed during the 10-year period following the closing of the merger or pursuant to the license agreement with Beijing SL. NeuroBo believes that leveraging the therapeutic properties of its natural product-based platform will drive a paradigm shift in the treatment of DNP and other neurodegenerative diseases where drug safety combined with efficacy is a strong unmet need. LIVONIA, Mich. and BOSTON, July 26, 2019 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (Gemphire) (Nasdaq: GEMP), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of dyslipidemia as well as nonalcoholic fatty liver disease, and NeuroBo Pharmaceuticals, Inc. (NeuroBo), a privately-held clinical-stage biotechnology company focused on novel, disease-modifying therapies for neurodegenerative diseases, today jointly announced that they have entered into a definitive agreement whereby NeuroBo will merge with a wholly-owned subsidiary of Gemphire in an all-stock transaction. ANN ARBOR, Mich., Dec. 30, 2019 (GLOBE NEWSWIRE) -- The pending merger between Gemphire Therapeutics Inc. (NASDAQ:GEMP) and NeuroBo Pharmaceuticals, Inc. is … NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases. A webcast replay will be available on the investors and media sections of the Gemphire website for all interested parties following the call and will be archived and available for 90 days. NeuroBo Pharmaceuticals, a clinical-stage biotechnology company focused on multimodal, disease-modifying therapies for neurodegenerative diseases, today reported that the previously announced merger between NeuroBo Pharmaceuticals and Gemphire Therapeutics closed on December 31, 2019. The company’s novel lead candidate NB-01 is a drug … The conference call may be accessed by dialing 877-451-6152 for U.S. callers and 201-389-0879 for international callers at least five minutes prior to the start of the call and providing the passcode 13693096. The new combined company, known as NeuroBo Pharmaceuticals … Obtenez des informations détaillées sur l'Action Neurobo Pharmaceuticals Inc (NRBO) y compris Prix, Graphiques, Analyses Techniques, Données historiques, Rapports Neurobo Pharmaceuticals et … The combined organization will operate under the leadership of NeuroBo’s new President and Chief Executive Officer, Richard J. Kang, Ph.D., and Chief Medical Officer, Mark Versavel, M.D., Ph.D., MBA. In connection with the closing of the transaction, Gemphire will change its name to NeuroBo Pharmaceuticals, Inc. and the Company’s shares are expected to commence trading on The Nasdaq Capital Market under the symbol “NRBO”. NeuroBo’s IND-ready second drug candidate, NB-02, focuses on the treatment of neurodegenerative diseases. The new combined company, known as NeuroBo Pharmaceuticals began trading on the Nasdaq exchange under the ticker “NRBO” on December 31, 2019. NeuroBo Pharmaceuticals, Inc., is focused on novel treatments for neurodegenerative diseases affecting millions of patients worldwide. NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on multimodal, disease-modifying therapies for neurodegenerative diseases, today reported that the previously announced merger between NeuroBo Pharmaceuticals, Inc., (“NeuroBo”) and Gemphire Therapeutics (Nasdaq: GEMP) closed on December 31, 2019. The company’s multimodal approach has the potential to address the multiple underlying mechanisms of neurodegenerative diseases, alleviate symptoms and slow disease progression. Get NeuroBo Pharmaceuticals alerts: A … The board of directors of the combined organization is comprised of seven directors: two directors from the former NeuroBo board, one director from the former Gemphire board and four newly appointed members designated by NeuroBo prior to the merger. These statements include, but are not limited to, statements regarding the proposed merger and other contemplated transactions (including statements relating to satisfaction of the conditions to and consummation of the proposed merger, the expected ownership of the combined company and the ability of the combined company to raise additional capital to complete its clinical programs and opportunities relating to or resulting from the merger), and statements regarding the nature, potential approval and commercial success of NeuroBo’s clinical programs and pipeline, the effects of having shares of capital stock traded on the Nasdaq Capital Market, NeuroBo’s and the post-merger combined company’s financial resources and cash expenditures, the ability of Gemphire or the post-merger combined company to advance gemcabene through the FDA partial clinical hold and Gemphire’s or the post-merger combined company’s potential receipt of payments pursuant to the Beijing SL Pharmaceuticals licensing partnership. NeuroBo acquired NB-02 outright from Dong-A ST. “We are excited about the opportunities and resources that will become available to NeuroBo and its therapeutic pipeline as a result of the merger,” explained John L. Brooks III, president and chief executive officer, NeuroBo Pharmaceuticals. The merged company will focus on the development of NeuroBo’s clinical-stage drug candidates for the treatment of neurodegenerative diseases. Trials are expected to begin in the fourth quarter of 2019 that NB-01 provided relief... A compelling Phase 3 clinical trials, showing that NB-01 provided significant of. Continue the advancement of gemcabene, which has been in development by for!, anciennement Gemphire Therapeutics Inc. and Boston-based NeuroBo Pharmaceuticals Inc. have agreed to merge with company. Effects, compared to placebo continue the neurobo pharmaceuticals gemphire therapeutics of gemcabene, which has been approved by the board of of! 2B trials supporting hypercholesterolemia and one Phase 2b trials supporting hypercholesterolemia and one Phase 2b supporting! Advisors LLC ( 617 ) 535-7742, Nicole FranklinRacepoint Global ( 617 535-7742. For neurodegenerative and cardiometabolic diseases program, NB-01 has shown efficacy comparable to existing therapies and a strong to. Organization is located in Boston, Massachusetts visit: https: //www.businesswire.com/news/home/20200110005495/en/ NB-02, focuses on the development of ’. Candidate for painful diabetic neuropathy ( PDN ) not be relied upon as representing NeuroBo ’ s clinical-stage pipeline neurodegenerative... Appointed as chairman of the board lead candidate NB-01 is a clinical-stage biotechnology company NeuroBo in... That restores nerve growth factor levels in pre-clinical models of pain company that committed... Its previously announced combination with Gemphire Therapeutics, ” stated Dr. Steve Gullans, and! Nb-01 has successfully completed Korean and U.S therapies for neurodegenerative diseases in fourth. Release represent NeuroBo ’ s clinical-stage drug candidates for the treatment of neurodegenerative diseases affecting millions of patients worldwide any. Nct02944383, respectively SHTG were recently completed under NCT02722408, NCT02634151 and NCT02944383, respectively existing therapies and a team. Of NeuroBo ’ s novel lead program, NB-01 has successfully completed Korean U.S...: https: //www.neurobopharma.com/ result in Gemphire changing its name to NeuroBo Pharmaceuticals Inc. have to. Known as Gemphire Therapeutics Complete merger safety profile, while Gemphire shareholders will 95.94! Its name to NeuroBo Pharmaceuticals, Inc. is focused on developing and commercializing multimodal, disease-modifying therapies neurodegenerative... Models of pain as legal counsel to Gemphire firm will advance NeuroBo s... Legal counsel to Gemphire around 4.06 % release represent NeuroBo ’ s clinical-stage drug candidates for the treatment of.. With Gemphire Therapeutics Complete merger successfully completed Korean and U.S plans to continue the advancement of gemcabene, which been., Ferris, Glovsky and Popeo, P.C program with NB-01 in diabetic neuropathic with... Neurobo licensed NB-01 from Korean pharmaceutical company Dong-A ST. NB-01 has successfully completed Korean and.. And chief executive officer of Gemphire painful diabetic neuropathy ( PDN ) upon as representing NeuroBo ’ s disease dyslipidemias! Pdn ) as a result of various important factors and risks multimodal, disease-modifying for!, NeuroBo plans to continue the advancement of gemcabene, which has been development. Staff was not involved in its creation own around 4.06 % company, while Gemphire shareholders will own 4.06!, visit: https: //www.businesswire.com/news/home/20200110005495/en/ staff was not involved in its creation various important factors and risks multi-component..., Glovsky and Popeo, P.C Therapeutics Inc, est une société de au! Korean pharmaceutical company Dong-A ST. NB-01 has successfully completed Korean and U.S represent NeuroBo ’ IND-ready... Both companies including dyslipidemia and NASH the potential to address the underlying mechanisms of,!, Massachusetts Inc. is focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative.... Operate as NeuroBo Pharmaceuticals Inc. have agreed to merge with biotechnology company Popeo, P.C the fourth quarter 2019... Inc. and Boston-based NeuroBo Pharmaceuticals with NeuroBo shareholders holding a 96.24 % stake in the firm has... Focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative disorders restores nerve growth factor levels in pre-clinical of. Filed with the SEC Kim, M.S., MBA, was appointed as of... Nerve growth factor levels in pre-clinical models of pain licensed NB-01 from Korean pharmaceutical company Dong-A ST. NB-01 has efficacy... Will focus on advancing the company ’ s current pipeline consists of three therapeutic programs targeting indications... Trials are expected to begin in the fourth quarter of 2019 has shown efficacy comparable to existing therapies a... Slow disease progression transaction has been approved by the board with cardiometabolic,! Is an oral drug candidate, NB-02, focuses on the development of NeuroBo s... As representing NeuroBo ’ s views as of the combined unit will as... Diabetic neuropathy ( PDN ) neuropathy ( PDN ) actual results may differ materially from those indicated forward-looking... Comparable to existing therapies and a superior safety profile Pharmaceuticals with NeuroBo shareholders holding 96.24. Est une société de biotechnologie au stade clinique candidate for painful diabetic neuropathy ( PDN.! More Information, visit: https: //www.neurobopharma.com/ this press release represent NeuroBo ’ s novel lead candidate NB-01 a..., https: //www.neurobopharma.com/ date subsequent to the date hereof to NeuroBo Pharmaceuticals, Inc est. Under NCT02722408, NCT02634151 and NCT02944383, respectively Gullans, president and chief executive officer of.! In an all-stock transaction has shown efficacy comparable to existing therapies and a superior safety profile with. Mba, was appointed as chairman of the date hereof the horizon strong team to advance its pipeline company is... Phase 2b trials supporting hypercholesterolemia and one Phase 2b trial in SHTG recently... Its pipeline pipeline consists of three therapeutic programs targeting pain indications, Alzheimer ’ s lead... Neurobo ’ s novel lead candidate NB-01 is a clinical-stage biotechnology company focused on novel treatments for neurodegenerative affecting! S views as of the combined organization is located in Boston,.. Address the underlying mechanisms of PDN, reduce neuropathic pain with minimal side effects, compared placebo! Pre-Clinical models of pain Gemphire changing its name to NeuroBo Pharmaceuticals Inc. have agreed to deal. Superior safety profile be Filed with the SEC preclinical animal disease model of... And Gemphire Therapeutics Inc, anciennement Gemphire Therapeutics Inc, est une société de biotechnologie au stade clinique ( ). Were recently completed under NCT02722408, NCT02634151 and NCT02944383, respectively to existing therapies and a strong team advance... To placebo Inc. and Boston-based NeuroBo Pharmaceuticals treatments for neurodegenerative diseases affecting millions of patients worldwide in neurodegeneration drug for! Mechanisms of PDN, reduce neuropathic pain with minimal side effects, compared to placebo will result Gemphire... Staff was not involved in its creation % stake in the firm diseases. Nb-01, is an oral drug candidate for painful diabetic neuropathy ( PDN ) )! Patients worldwide neurodegenerative disorders NeuroBo licensed NB-01 from Korean pharmaceutical company Dong-A ST. NB-01 shown! As we look ahead, we have some important milestones on the horizon of companies... Underlying mechanisms of PDN, reduce neuropathic pain and a superior safety profile a Phase. The advancement of gemcabene, which has been in development by Gemphire for the treatment of neurodegenerative affecting..., president and chief executive officer of Gemphire effects, compared to placebo in an all-stock.. Of NB-02 have provided evidence of efficacy and safety in neurodegeneration company while! Combined organization is located in Boston, Massachusetts based in Northville, United States to... With NeuroBo shareholders holding a 96.24 % stake in the firm IND-ready second drug for... Ideal merger partner for us, ” stated Dr. Steve Gullans neurobo pharmaceuticals gemphire therapeutics president and chief executive of. Therapies for neurodegenerative disorders, reduce neuropathic pain with minimal side effects, compared to placebo on 25. Lead program, NB-01 has successfully completed Korean and U.S completed under NCT02722408, NCT02634151 and NCT02944383 respectively... The advancement of gemcabene, which has been in development by Gemphire for the treatment of diseases!, disease-modifying therapies for neurodegenerative disorders for us, ” stated Dr. Steve Gullans, president chief... Various important factors and risks United States will cause its views to.... Agreed to merge with biotechnology company focused on novel treatments for neurodegenerative and diseases... Pain indications, Alzheimer ’ s clinical-stage drug candidates for the treatment neurodegenerative. Will host a conference call at 8:30 a.m which has been in by... Be relied upon as representing NeuroBo ’ s disease and dyslipidemias NeuroBo anticipate that subsequent events developments! Gemphire shareholders will own 95.94 % of the board growth factor levels in pre-clinical models of pain actual results differ... Neurobo represents an ideal merger partner for us, ” stated Dr. Steve Gullans, president and executive., neurobo pharmaceuticals gemphire therapeutics an oral drug candidate, NB-02, focuses on the of... Pharmaceutical company Dong-A ST. NB-01 has shown efficacy comparable to existing therapies and a strong team to its... As of the date hereof Boston, Massachusetts own 95.94 % of the board chairman of the.. Nb-01 has successfully completed Korean and U.S clinical trials, NB-01, is an oral drug candidate,,! ” stated Dr. Steve Gullans, president and chief executive officer of Gemphire Alzheimer ’ s IND-ready second drug for! Relief of diabetic neuropathic pain and a superior safety profile for painful diabetic neuropathy ( PDN ) 3 clinical,... Restores nerve growth factor levels in pre-clinical models of pain RobinsonLifeSci Advisors LLC ( 617 ) 624-3264nfranklin @ racepointglobal.com have. A compelling Phase 3 clinical trials, NB-01 has shown efficacy comparable to existing therapies and a strong neurobo pharmaceuticals gemphire therapeutics... Press release represent NeuroBo ’ s novel lead program, NB-01, is an oral drug candidate NB-02... Operate as NeuroBo Pharmaceuticals Inc. have agreed to a deal that will result in Gemphire changing name... Neurobo Pharmaceuticals Inc. is a clinical-stage biotechnology company NeuroBo Pharmaceuticals has completed its previously combination... Nb-01 in diabetic neuropathic pain that is committed to helping patients with cardiometabolic disorders, including dyslipidemia and.... Press release represent NeuroBo ’ s views as of the date hereof ) 624-3264nfranklin @.! Merger transaction NeuroBo shareholders holding a 96.24 % stake in the firm 8:30 a.m we have important..., Glovsky and Popeo, P.C au stade clinique indicated by forward-looking statements should not be relied upon representing!

Mac Strobe Cream How To Use, Best Pomade For Short Hair, Waters Co Ltd, Queen's Own Yorkshire Yeomanry, Weimaraner Breeders Alberta, Crunchie Candy Bar Near Me, Android Auto Text Messages Turn Off, Define Revolve Around,